Linda T. Vahdat, MD, from the Weill Cornell Medical College, discusses the combination of eribulin mesylate and trastuzumab as a first-line therapy for HER2-positive metastatic breast cancer.
Linda T. Vahdat, MD
Advertisement
Articles by Linda T. Vahdat, MD
Dr. Linda Vahdat, from New York-Presbyterian Hospital, Discusses the Side Effects of Halaven
Dr. Linda Vahdat, from the New York-Presbyterian Hospital, Compares Halaven and Ixempra Neuropathy
Advertisement
Latest Updated Articles
Dr. Vahdat Compares Halaven and Ixempra NeuropathyPublished: December 22nd 2011 | Updated:
Dr. Vahdat Discusses the Side Effects of HalavenPublished: January 18th 2012 | Updated:
Dr. Vahdat on Frontline Eribulin Plus Trastuzumab in MBCPublished: February 26th 2013 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5